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Purpose: To quantify the health related quality of life in primary immunodeficien-
cy patients. Materials and Methods: We used generic health status and general 
psychological health questionnaires to determine the range of issues that needed to 
be considered in examining the burden of common variable immunodeficiency 
(CVID). Results: The health status of patients with CVID was lower than that ob-
served in normal subjects. Overall, Role-Physical and General Health scales corre-
lated with a poorer clinical status. Surprisingly, the duration of disease did not influ-
ence health status. Being female, older, General Health Questionnaire-positive and 
alexithymic proved to be major risk factors associated with a poor health status. Pa-
tients with chronic lung disease and chronic diarrhea had the lowest values on the 
Medical Outcome Study, Short Form SF-36 (SF-36) scales. Disease severity per-
ception was associated with the General Health Questionnaire and alexithymia sta-
tus. Limitations in daily activities as a result of lower physical health were the ma-
jor problems facing common variable immunodeficiency patients. Conclusion: 
Our data underlined the importance of conducting a periodical health related quality 
of life assessment on patients with primary antibody deficiencies and, moreover, 
stressed the necessity of providing psychological support to at risk patients.
Key Words:    Common Variable Immunodeficiency, Health Related Quality of 
Life, SF-36, General Health Questionnaire-12, GHQ-12
INTRODUCTION
Common variable immunodeficiency (CVID) is the most frequent symptomatic 
antibody deficiency, characterized by low levels of serum immunoglobulins and 
impaired antibody response.1-3 CVID may occur at any age, demonstrating pre-
dominance in the adult age group. The clinical spectrum includes respiratory in-
fections, gastrointestinal diseases, autoimmune diseases, granulomatous manifes-
tations, and cancers.4,5 Long-term administration of immunoglobulins reduces the 
incidence of infections. However, despite IgG replacement, CVID patients may Isabella Quinti, et al.
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plete blood counts, lymphocyte subsets, chemistries, serum 
immunoglobulin levels, and culture tests were performed 
four times per year. Chest and sinus computerized tomogra-
phy (CT) scans were performed every four years, and gas-
trointestinal endoscopy with biopsy was performed every 
two years. All data were processed in a database and sent to 
the Interuniversity Computing Centre responsible for pro-
cessing and analyzing the data. All 112 adult CVID patients 
referred to our center were recruited, and 16 refused to par-
ticipate. Data were analyzed on the same day of their peri-
odical clinical assessment. The ninety-six patients (50 
males and 46 females) who agreed to participate to our 
study had a mean age of 48.2±17 years. Fifty-two patients 
were less than 50 years of age (group 1) and 44 were older 
than 50 years (group 2). The mean age at diagnosis was 
36±17.5 years. The mean duration of disease since diagno-
sis was 10.7 years (range 5-36). The majority of patients 
(87.5%) were receiving intravenous gammaglobulin every 2 
or 3 weeks in a day hospital setting. Twelve patients self-in-
fused subcutaneous immunoglobulins at home with a 
monthly clinical follow-up at our out-patient service. Be-
fore clinical examination and immunoglobulin therapy, pa-
tients were asked to fill in the four questionnaires concern-
ing their HRQoL, general health status, and the possible 
presence of depression/anxiety and alexithymia.
Outcome measures
SF-36
Although designed as a generic health status indicator for use 
in population surveys and health policy evaluation studies, 
the SF-36 (8) can also be used as an outcome measure. The 
SF-36 includes 36 items in a Likert-type or forced-choice 
format, intended to measure the following eight dimensions: 
physical functioning (PF, limitations in performing physical 
activities such as bathing or dressing), role-physical (RP, lim-
itations in work and other daily activities as a result of physi-
cal health), bodily pain (BP, how severe and limiting is pain), 
general health (GH, how general personal health is perceived 
by the patient), vitality (VT, feeling tired and worn out vs. 
feeling energetic), social functioning (SF, interference with 
normal social activities due to physical or emotional prob-
lems), role-emotional (RE, limitations in work and other dai-
ly activities as a result of emotional problems), and mental 
health (MH, feeling nervous and depressed vs. peaceful, hap-
py and calm). Scores for each domain range from 0 to 100, 
with higher scores indicating better health status. Two addi-
still suffer from respiratory infections, caused by encapsulat-
ed bacteria, leading to permanent lung damage.6,7 Quantify-
ing the health related quality of life (HRQoL) in primary im-
munodeficiency conditions has relatively recently began as 
an effort to document the outcomes of therapeutic interven-
tion, and in order to do so, investigators have begun to use 
generic measures such as the Medical Outcome Study, Short 
Form SF-368/SF-129 or Life Quality Index.10 The aims of our 
study were to determine the range of issues that need to be 
considered in examining the burden of CVID and to evaluate 
HRQoL and psychological status of patients attending our 
day-hospital Unit, using a generic health status questionnaire 
and general psychological health questionnaires. Moreover, 
we intended to compare the evaluations of disease severity 
from both the patient and the physician perspectives. The un-
derlying hypothesis was that CVID patients have a low 
HRQoL and, according to the global severity assessment of 
his/her own disease, mental and psychological aspects, 
which contribute to the burden of the disease, should be con-
sidered. Moreover, we investigated if risks of depression/
anxiety and alexithymia could be associated with different 
perceptions of disease severity and health status.
MATERIALS AND METHODS
　　　
Study subjects
For this observational, short-term longitudinal cohort study, 
performed in a day hospital setting, patients’ participation 
was obtained via signed informed consent. The project was 
approved by our Institute Ethical Committee. The study 
was conducted during the period of January-October 2010. 
HRQoL was tested twice in a six month period. The entry 
criteria for this study were: 1) a diagnosis of CVID and 2) a 
clinical follow-up of at least five years at our center for pri-
mary immunodeficiencies. CVID diagnosis was made in 
patients over two years of age by approved criteria;2 includ-
ing low levels of serum IgG, IgA, and/or IgM; antibody de-
ficiency with impaired response to tetanus and pneumococ-
cal antigen immunization; peripheral B cell numbers of less 
than 2%; and exclusion of hypogammaglobulinemia due to 
other primary or secondary immunodeficiencies. Detailed 
information on personal data, date of diagnosis, immuno-
logical data and clinical manifestations, as well as route and 
dosage of immunoglobulin replacement were collected on a 
yearly basis from the initial diagnosis via a questionnaire 
filled in by a physician of our center. For each patient, com-HRQoL in CVID
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tions, “In your opinion, compared to other patients with the 
same condition, how severe is the disease of patient X?” and 
“In your experience, how severe is your disease?”, respec-
tively. Answers were given on a 5-point scale: “very mild”, 
“mild”, “moderate”, “severe”, and “very severe”. The physi-
cian recorded the evaluation at the end of the visit, and the 
patients recorded their evaluations after completing the oth-
er questionnaires.
Statistical analysis
In order to compare PtGA and PhGA, we created three cat-
egories: “Agreement”, PtGA was equal to PhGA; “Patient 
underestimates”, PtGA was lower than PhGA; “Patient 
overestimates”, PtGA was higher than PhGA. Cohen’s kap-
pa was calculated to measure the agreement between the 
evaluations of severity by both patients and physicians. A 
value of 1 indicated perfect agreement, while a value of 0 
indicated that agreement was no better than chance. After 
univariate analyses, two logistic regression models were 
tested in order to investigate the possible determinants of 
underestimation or overestimation of severity by the patient. 
The dependent variables were, respectively, “patient under-
estimates” and “patient overestimates” vs. others. Indepen-
dent variables were: gender, age (dichotomised cut-off of 
50 years), GHQ-12 (case/non-case), TAS-20 (alexithymia/
no-alexithymia). For all subjects, sex, age, duration of dis-
ease, presence of chronic lung disease, chronic sinusitis and 
chronic diarrhea, were compared using Wilcoxon-Mann-
Whitney tests. Quality of life scores eight areas, and the 
overall physical and mental scores were calculated based 
on the SF-36 manual. Then, one-sample z-test was used to 
compare our study group with the general Italian popula-
tion. To internally compare the overall physical and mental 
quality of life scores in various subgroups in our CVID 
study group, the Wilcoxon-Mann-Whitney test was used. 
Statistical analyses included the t-test for independent sam-
ples and the chi-square test as well as a logistic regression 
analysis to assess the independent role of factors of interest 
in determining poor HRQoL. All analyses were performed 
using the Stata version 11 software.
RESULTS
 
Chronic infections were the major cause of morbidity in 
CVID
Forty-two percent of patients were affected by chronic si-
tional summary measures, the physical (PCS) and mental 
component scores (MCS), cross-culturally validated in the 
framework of the International Quality of Life Assessment   
project for the Italian version of the SF-36,11 were also ob-
tained. As controls for general health status, we used the Ital-
ian Normative Values.11
GHQ-12
The General Health Questionnaire-1212 is a self-adminis-
tered 12-item questionnaire designed to measure psycho-
logical distress and to detect current non-psychotic psychiat-
ric disorders, such as depression and anxiety. The reliability 
and validity of the Italian version have been tested in sever-
al diseases, including dermatological conditions.13 Answers 
are given on a four-point scale; for instance, the item “in the 
last weeks, did you feel under strain?” invites the following 
answers: “no”, “not more than usual”, “more than usual”, 
and “much more than usual”. When scored with the binary 
method (0-0-1-1), the GHQ-12 can be used as a screening 
tool to detect minor non-psychotic psychiatric disorders, 
yielding final scores that range from 0 to 12. Operationally, 
patients scoring 4 or more were considered as “GHQ-posi-
tive” (GHQ+): at risk of anxiety/depression.
TAS-20
The 20-item Toronto Alexithymia Scale (TAS-20) ques-
tionnaire14,15 was used to evaluate alexithymia, i.e., the diffi-
culty in identifying and describing feelings. It gives three 
subscale scores, measuring, respectively, the difficulty in 
identifying feelings, the difficulty in describing and com-
municating feelings, and the tendency to focus on the con-
crete details of external events rather than on feelings, fan-
tasies, and other aspects of one’s own inner experience 
(“externally oriented thinking”). There is evidence of inter-
nal consistency, test-retest reliability and factorial validity 
for the Italian version of the TAS-20.16 The item ratings un-
der each TAS-20 scale were added together to give sub-
scale scores. Then, these scores were summed to give the 
total score. The classical cut-offs are: below 52, people are 
classified as non-alexithymic; between 52 and 60, border-
line alexithymic; and more than 60, alexithymic.
PGA
For each patient, an overall clinical severity evaluation of 
the disease was given by the physician and by the patient 
him/herself. The Physician Global Assessment (PhGA) and 
the Patient Global Assessment (PtGA) comprised the ques-Isabella Quinti, et al.
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apy (data not shown).
In our study, trough IgG levels did not correlate with fre-
quency of respiratory infections, which agrees with the data 
of a recently published multicenter prospective study.17  For 
the multivariate analysis performed in order to determine 
independent predictors of CVID-associated clinical condi-
tions, we did not find an increased risk of pneumonia, bron-
chiectasis, or acute and chronic sinusitis in patients who 
had different IgG trough levels, except for those who had 
IgG trough levels below 400 mg/dL.17
Being female, older, General Health Questionnaire-
positive and alexithymic proved to be major risk factors 
associated with a poor health status
Female, older, GHQ-positive and alexithymic individuals 
had statistically significant lower mean SF-36 scale values 
(p<0.05) compared to male, younger, GHQ-negative, non-
alexithymic individuals (Table 1). GHQ-positive patients 
(at risk of minor psychiatric non psychotic diseases such as 
depression/anxiety) or alexithymic individuals (who have 
difficulty in identifying and describing feelings) showed the 
worst values for evaluating QoL. SF-36 summary measures 
for physical and mental scales (PCS-MCS) demonstrated 
that GHQ-positive patients had lower mean values for 
MCS (34±13) in comparison with GHQ-negative patients 
(47±10) (p<0.05), while alexithymic individuals had lower 
values for PCS (33±7) in comparison to non-alexithymic 
individuals (42±13) (p<0.05) and lower values for MCS 
(36±12) in comparison to non-alexithymic individuals 
(45±12) (p<0.05). 
Disease severity perception was associated with GHQ 
and alexithymia status 
Cohen’s kappa was calculated to measure the agreement be-
tween severity evaluations by the patients and by physicians 
(0.16). PhGA was greater in alexithymic CVID patients and 
GHQ-positive CVID patients (57% and 48%, respectively) 
(Table 1). Only 15% of alexithymic individuals and only 
25% of GHQ-positive patients considered their disease se-
verity as “high”. With a logistic regression analysis, consid-
ering “underestimation” of the disease severity by the pa-
tient as the dependent variable and gender, age, GHQ-
positive status, and presence of alexithymia as independent 
variables, a statistically significant result was only observed 
for those less than 50 years of age (p=0.045). For “overesti-
mation”, no variables were statistically significant; however, 
GHQ-positive patients had an OR of 2 (95% CI 0.6-6.9) . 
nusitis at the time of the study. A high prevalence (65.6%) 
of patients with chronic lung disease (CLD) and bronchiec-
tasis, confirmed by chest CT scanning, was present at the 
time of the survey. The prevalence was higher than 50% for 
both age groups. The 63 individuals with CLD were slight-
ly older (mean age 49.8±17) than those without CLD 
(mean age 43.8±15.6); 76% of the subjects with CLD had 
one or more episodes of acute bronchitis or acute sinusitis 
during the study period. One of the subjects with CLD was 
using oxygen. Two patients died during the study period, 
one for non-Hodgkin B cell lymphoma and one for post-
splenectomy sepsis. Twenty-two percent of the patients 
with chronic lung disease were taking daily prophylactic 
antibiotics (20). Chronic diarrhea was observed in 22.4% of 
patients. The percentage of affected patients was higher in 
the older age group (>50 years of age). Twenty-one patients 
(22.6%) had CLD, chronic diarrhea and sinusitis at the 
same time. We found no difference in the prevalence of 
chronic diseases between males and females. Other medical 
problems commonly seen in adults including hypertension 
and type II diabetes were observed in 18% and 9% of pa-
tients, respectively.
The health related quality of life was low; mental health 
scales are less affected than physical scales
The SF-36 mean values of all CVID patients and of differ-
ent age groups (25-34 years; 35-44 years; 45-54 years; 55-
64 years) were compared to the normative data of the Ital-
ian population (Fig. 1). Health status in CVID patients was 
statistically significant lower than that observed in normal 
subjects. The mental domain scales (Vitality, Social Func-
tioning, Role-Emotional, Mental Health) had values close 
to those reported in normal subjects in all age groups, 
whereas the physical mean value scales (Physical Function-
ing, Role-Physical, Bodily Pain, General Health) were low-
er than the normative data (p<0.05). Role-Physical and 
General Health scales showed the lowest values among 
CVID patients, overall. Patients with CLD (p<0.05) and 
chronic diarrhea (p<0.05) had lower values on SF-36 scales   
with respect to patients with no chronic diseases, while 
chronic sinusitis had no effect on HRQoL (Table 1). No 
correlations were found for IgG serum levels and health 
status assessed by PCS and MCS or by GHQ-12 (comput-
ed using the classical Likert score). We found no differenc-
es in HRQoL between patients on intravenous immuno-
globulin therapy (IVIG) and patients who self-administered 
subcutaneous immunoglobulins (SCIG) as an in-home ther-HRQoL in CVID
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Fig. 1. SF-36 scales, mean values in (A) CVID patients vs. normal subjects - Italian normative. (B) CVID patients vs. normal subjects (25-34 years). (C) CVID 
patients vs. normal subjects (35-44 years). (D) CVID patients vs. normal subjects (45-54 years). (E) CVID patients vs. normal subjects (55-64 years). Higher 
scores denote better health SF-36 scales. PF, physical functioning (limitations in performing physical activities such as bathing or dressing); RP, role-physi-
cal (limitations with work and other daily activities as a result of physical health); BP, bodily pain (how severe and limiting is pain); GH, general health (how 
general personal health is evaluated by the patient); VT, vitality (feeling tired and worn out vs. feeling full of energy); SF, social functioning (interference 
with normal social activities due to physical or emotional problems); RE, role-emotional (limitations with work and other daily activities as a result of emo-
tional problems); MH, mental health (feeling nervous and depressed vs. peaceful, happy and calm). CVID, common variable immunodeficiency; SF-36, 
Shot From-36. Normal subjects, Italian Normative
11). *p<0.05 t-test.
 Normal subjects n.2031    CVID patients n.96
 Normal subjects n.373    CVID patients n.14
 Normal subjects n.367    CVID patients n.18
 Normal subjects n.367    CVID patients n.15
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DISCUSSION
HRQoL is a subjective perception of health status (includ-
ing disease and treatment) concerning physical, psychologi-
cal, and social functioning and wellbeing. When consider-
ing the burden of a disease, the health domain is the most 
pertinent aspect of quality of life and on which this study 
focused. Self-completed measures, acceptable to patients, 
are available for use in clinical settings with adequate sensi-
tivity and specificity in their ability to identify problems 
A second patient assessment was performed over a six-
month period using the same questionnaires in order to 
confirm the results obtained at the first assessment. The re-
sults observed in the first and second assessment of the 
mean values of SF-36 summary measures allowed for iden-
tification of patients who reported a change in their GHQ 
status. The percentage of GHQ-positive patients was 27% 
at the first observation and 29% at the second observation. 
As expected, in subjects who had an increase in GHQ score, 
we observed a reduction in MCS values as a result of wors-
ening mental health.
Table 1. SF-36 and Alexithymia Mean Values and Standard Deviation for Clinical Characteristics of CVID Patients* 
  n PF RP BP GH VT SF RE MH PCS MCS Alexithymia
All 96 72 (25) 47 (42) 67 (26) 39 (24) 55 (22) 69 (22) 68 (40) 66 (20) 40 (12) 43 (12) 44 (12)
    Males 50 78 (24) 59 (41) 73 (25) 44 (27) 62 (20) 72 (23) 74 (38) 69 (20) 43 (12) 45 (12) 43 (11)
    Females 46  66 (25)
†  34 (40)
†  60 (26)
† 34 (20)  47 (21)
† 66 (21) 62 (42) 63 (19)  36 (11)
† 42 (12) 46 (13)
Age  
    <50 yrs 52 84 (19) 56 (42) 74 (26) 43 (27) 59 (21) 69 (24) 79 (33) 68 (19) 44 (12) 44 (12) 42 (12)
    ≥50 yrs 44  58 (25)
†  39 (40)
†   59 (25)
† 35 (21) 51 (22) 70 (20)  55 (43)
† 64 (21)  34 (11)
† 43 (13) 48 (12)
Duration of disease 
    ≤8 yrs 47 73 (28) 49 (42) 69 (28) 42 (23) 55 (20) 68 (24) 72 (38) 63 (20) 41 (13) 43 (13) 46 (11)
    >8 yrs 46 71 (23) 44 (42) 65 (26) 37 (27) 56 (24) 69 (21) 64 (42) 68 (20) 39 (12) 44 (12) 44 (13)
GHQ status  
    GHQ positive 25 62 (25) 28 (37) 52 (27) 30 (19) 37 (19) 55 (19) 37 (39) 51 (20) 36 (12) 34 (13) 50 (14)
    GHQ negative 69  76 (25)
†  55 (42)
†  73 (24)
†  43 (26)
†  62 (19)
†  75 (21)
†  80 (34)
†  72 (17)
† 41 (12)  47 (10)
†  42 (11)
†
Alexithymia  
    Negative 74 78 (24) 53 (43)  70 (26) 40 (25) 57 (21) 72 (23) 74 (37) 69 (20) 42 (13)  45 (12)  
    Positive (≥56) 15  51 (19)
†  27 (33)
† 56 (26) 36 (25) 45 (23)  61 (19)
†   40 (44)
†  52 (17)
†  33 (7)
†  36 (12)
†  
PtGA  
    Low 25 89 (18) 71 (37) 79 (21) 56 (27) 66 (19) 75 (22) 78 (29) 72 (17) 48 (11) 44 (11) 41 (13)
    Medium 46 69 (26) 43 (43) 66 (27) 36 (20) 51 (21) 68 (21) 70 (42) 63 (20) 38 (12) 43 (12) 45 (12)
    High 22  63 (23)
†  32 (36)
†  56 (26)
†  29 (22)
†  52 (23)
† 66 (24) 58 (43) 66 (21)  34 (10)
† 43 (14) 46 (12)
PhGA  
    Low 15 78 (22) 55 (45) 74 (26) 42 (22) 54 (19) 76 (17) 84 (30) 68 (17) 43 (13) 45 (10) 45 (15)
    Medium 43 81 (25) 52 (46) 73 (27) 41 (28) 60 (20) 71 (23) 72 (37) 69 (19) 42 (13) 44 (12) 41 (9)
    High 28 62 (24)  42 (37)
† 59 (23)  36 (21)
† 50 (24) 64 (22)  56 (44)
† 62 (21) 37 (9)  41 (12) 48 (13)
CLD  
    Present 62 70 (25) 41 (41) 63 (26) 37 (23) 54 (23) 65 (23) 60 (41) 63 (21) 38 (12) 41 (13) 44 (11)
    Absent 29 79 (25)  61 (43)
†  76 (26)
† 46 (27) 60 (19)  77 (20)
†  86 (30)
† 72 (15) 43 (13) 47 (9) 44 (15)
Sinusitis  
    Present 48 73 (25) 44 (43) 66 (28) 36 (23)  54 (22) 68 (22) 65 (42) 65 (22) 39 (12) 42 (13) 42 (11)
    Absent 43 72 (27) 51 (42) 69 (25) 45 (26) 57 (22) 70 (22) 72 (37) 67 (18) 41 (13) 44 (11) 47 (13)
Diarrhea  
    Present 42 65 (26) 37 (40) 60 (29) 34 (24) 51 (23) 65 (24) 54 (41) 63 (22) 36 (12) 41 (13) 46 (12)
    Absent 47  79 (23)
†  54 (43)
†  74 (24)
†  45 (25)
† 59 (20)  74 (19)
†  81 (34)
† 68 (18)  43 (12)
† 45 (11) 43 (13)
SF-36: PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH, mental 
health; PCS, physical component summary;  MCS, mental component summary; CLD, chronic lung disease; PhGA, physician global assessment; PtGA, 
patient global assessment; CVID, common variable immunodeficiency; GHQ, General Health Questionnaire.  
*p<0.05. 
†Totals may vary because of missing values.HRQoL in CVID
Yonsei Med J   http://www.eymj.org   Volume 53   Number 3   May 2012 609
were judged by the physician (PhGA) as seriously affected 
reported a lower health status than the others. 
Our data underlined the importance of conducting a peri-
odical Health related quality of life assessment on patients 
with primary antibody deficiencies and other chronic ill-
nesses. In fact, as expected, patients with chronic lung dis-
ease and chronic diarrhea had the lowest health related 
quality of life values; however, being female, older, General 
Health Questionnaire-positive and alexithymic also proved 
to be major risk factors associated with a poor health status. 
Finally, we suggest that in a comprehensive evaluation of 
HRQoL assessment should be performed in each patient in 
order to document the outcomes of clinical management 
and therapeutic intervention. Moreover, we confirmed that 
it is necessary to care for at risk patients with psychological 
support throughout their lifetime.
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